Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer

NCT05453799 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT05453799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05453799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Suspended
Start date
July 21, 2022
Completion date
September 5, 2030
Enrollment
54 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced thyroid gland anaplastic carcinoma, metastatic thyroid gland anaplastic carcinoma, metastatic thyroid gland oncocytic carcinoma